GlassScriptPhysician profile
Paul David Jantzi
NPI 1114090867
$13,557.34
in general payments reported to CMS, 2019-2025
42 companies · $2,800 in 2025
The $2,800 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,238 · 2020: $871 · 2021: $1,457 · 2022: $1,876 · 2023: $2,207 · 2024: $2,109 · 2025: $2,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,969 · Education: $107 · Consulting Fee: $40.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,968.72 |
| Education | $106.93 |
| Consulting Fee | $40.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,612.34 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,773.36 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $1,757.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $741.57 | 2020-2025 | Cuvitru, Takhzyro, Aralast |
| Regeneron Healthcare Solutions, INC. | $625.31 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $610.14 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $596.97 | 2019-2025 | Xolair |
| Blueprint Medicines Corporation | $428.34 | 2023-2025 | Ayvakit |
| Pfizer INC. | $384.69 | 2019-2025 | |
| Incyte Corporation | $310.61 | 2022-2025 | Opzelura |
| Csl Behring | $300.71 | 2019-2025 | Hizentra |
| Pharming Healthcare, INC. | $287.32 | 2019-2025 | Ruconest |
| Galderma Laboratories, L.P. | $268.49 | 2025 | Nemluvio |
| Alk-Abello, INC | $261.97 | 2019-2024 | Odactra, Grastek, Ragwitek |
| Novartis Pharmaceuticals Corporation | $252.74 | 2019-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jantzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.